Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis

BACKGROUND AND AIMS: Tofacitinib is a Janus kinase inhibitor (JAKi) recently approved for the treatment of moderate to severe ulcerative colitis (UC) based on robust efficacy and safety data derived from OCTAVE clinical trials. Evidence on the outcomes of tofacitinib therapy in real-world UC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucaciu, Laura A., Constantine-Cooke, Nathan, Plevris, Nikolas, Siakavellas, Spyros, Derikx, Lauranne A.A.P., Jones, Gareth-Rhys, Lees, Charles W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721385/
https://www.ncbi.nlm.nih.gov/pubmed/34987608
http://dx.doi.org/10.1177/17562848211064004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721385/
https://www.ncbi.nlm.nih.gov/pubmed/34987608
http://dx.doi.org/10.1177/17562848211064004

Ejemplares similares